BEVERLY HILLS, Calif,
June 24, 2021 /PRNewswire/ -- GT
Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a
clinical stage immuno-oncology company focused on developing
innovative therapeutics based on the Company's proprietary natural
killer (NK) cell engager (TriKE™) protein biologic technology
platform, today announced that GT Biopharma CEO, Tony Cataldo will be presenting as a VIP speaker
at the upcoming Sir Anthony
Ritossa's Global Family Office Investment Summit in
Monaco from June 30 to July 2, 2021.
The Sir Anthony Ritossa's Global
Family Office Investment Summit in Monaco is one of a series of international
summits held annually as a platform for exceptional networking
between Family Offices and Thought Leaders from all over the world.
Summit delegations consist of prestigious family offices, private
investors, sheikhs, royal families and leading businesses from 30+
countries representing more than $4.5
trillion in wealth.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a
clinical stage biopharmaceutical company focused on the development
and commercialization of immuno-oncology therapeutic products based
on our proprietary TriKE™ NK cell engager platform. Our
TriKE™ platform is designed to harness and enhance the cancer
killing abilities of a patient's immune system's natural killer
cells (NK cells). GT Biopharma has an exclusive worldwide
license agreement with the University of
Minnesota to further develop and commercialize therapies
using TriKE™ technology. For more information, please visit
gtbiopharma.com.
Investor
Contact:
|
Investor and Media
Relations Contact:
|
Brendan
Payne
|
David
Castaneda
|
Client
Lead
|
David@gtbiopharma.com
|
Stern Investor
Relations, Inc.
|
414-351-9758
|
brendan.payne@sternir.com
|
|
212-362-1200
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/gt-biopharma-ceo-tony-cataldo-to-present-at-sir-anthony-ritossas-global-family-office-investment-summit-301318854.html
SOURCE GT Biopharma, Inc.